Edition:
India

Nanobiotix SA (NANOB.PA)

NANOB.PA on Paris Stock Exchange

6.07EUR
18 Oct 2019
Change (% chg)

€-0.20 (-3.19%)
Prev Close
€6.26
Open
€6.26
Day's High
€6.34
Day's Low
€6.01
Volume
137,149
Avg. Vol
59,700
52-wk High
€16.19
52-wk Low
€6.01

Latest Key Developments (Source: Significant Developments)

Nanobiotix H1 Net Loss Widens To 23.9 Million Euros
Wednesday, 4 Sep 2019 

Sept 4 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX ANNOUNCES HALF-YEAR FINANCIAL STATEMENTS AS OF JUNE 30, 2019.EXPECTING TO ADVANCE US CLINICAL TRIAL AUTHORIZATION PROCESS FOR HEAD AND NECK CANCERS IN Q4.REVENUE FOR THE FIRST HALF OF 2019 AMOUNTED TO €1.8M (H1 2018: €2.1M).OVERALL EXPENSES PROCEED ACCORDING TO PLAN, WITH A NET LOSS OF 12.6MEUR FOR 6 MONTHS PERIOD ENDING JUNE 30, 2018 AND 23.9MEUR FOR 6 MONTHS PERIOD ENDING ON JUNE 30, 2019.H1 OPERATING RESULT FOR PERIOD WAS A EUR 20.5M LOSS COMPARED TO EUR 13.0M (LOSS) IN H1 2018.HAD CASH AND FINANCIAL INVESTMENTS AT JUNE 30, 2019 OF €55.1M (31 DECEMBER 2018: €36.2M).H1 NET LOSS EUR 23.9 MILLION VERSUS LOSS OF EUR 12.6 MILLION YEAR AGO.AT JUNE 30, 2019, THE COMPANY’S DEBT AMOUNTED EUR 44.1 MILLION.  Full Article

Nanobiotix Q1 Revenue Amounted To 5,000 Euros
Tuesday, 30 Apr 2019 

April 30 (Reuters) - NANOBIOTIX SA ::REVENUE FOR THE FIRST QUARTER OF 2019 AMOUNTED TO €5K.CASH AVAILABILITY AS OF MARCH 31, 2019 AMOUNTED TO €40.9M.  Full Article

Laurent Levy, CEO, Increases Stake In Nanobiotix’S Capital
Friday, 26 Apr 2019 

Nanobiotix SA ::LAURENT LEVY, CEO, INCREASES STAKE IN NANOBIOTIX’S CAPITAL.NANOBIOTIX SA - LAURENT LEVY SUBSCRIBED TO 160,000 NEW SHARES THROUGH EXERCISE OF 160,000 BSPCE(2012-1) FOR A TOTAL AMOUNT OF EUR 960,000.NANOBIOTIX SA - NEW SUBSCRIPTION BRINGS LEVY'S OWNERSHIP TO 731,560 SHARES WHICH REPRESENTS 3.3% OF CAPITAL AND 5.5% OF VOTING RIGHTS OF CO.  Full Article

Nanobiotix Launches Capital Increase By Means Of Accelerated Bookbuild Offering
Monday, 8 Apr 2019 

April 8 (Reuters) - NANOBIOTIX SA ::JEFFERIES INTERNATIONAL LIMITED ("JEFFERIES") IS ACTING AS SOLE BOOKRUNNER FOR OFFERING.NANOBIOTIX LAUNCHES A CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOKBUILD OFFERING.TO ISSUE UP TO 2,566,666 NEW ORDINARY SHARES OF A NOMINAL VALUE OF EUR 0.03 ("NEW SHARES").ADMISSION OF NEW SHARES TO TRADING ON EURONEXT PARIS ARE EXPECTED TO OCCUR ON OR ABOUT APRIL 11, 2019.OFFERING WILL COMMENCE IMMEDIATELY AND IS EXPECTED TO END BEFORE MARKETS OPEN ON REGULATED MARKET OF EURONEXT PARIS TOMORROW.  Full Article

Nanobiotix Announces Hencify Received European Market Approval
Thursday, 4 Apr 2019 

April 4 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX ANNOUNCES FIRST EVER RADIOENHANCER TO RECEIVE EUROPEAN MARKET APPROVAL.THIS APPROVAL REPRESENTS SIGNIFICANT STEP FORWARD IN ESTABLISHING NBTXR3 AS A MAJOR ONCOLOGY TREATMENT.AFTER POSITIVE PHASE II/III DATA, THIS APPROVAL REPRESENTS SIGNIFICANT STEP FORWARD IN ESTABLISHING NBTXR3 AS A MAJOR ONCOLOGY TREATMENT.HENSIFY (NBTXR3) RECEIVED EUROPEAN MARKET APPROVAL (CE MARK) ENABLING COMMERCIALIZATION IN 27 EUROPEAN UNION COUNTRIES FOR TREATMENT OF LOCALLY ADVANCED SOFT TISSUE SARCOMA.POST-APPROVAL TRIALS ARE PLANNED ACROSS EUROPE AND DISCUSSIONS ON NEXT STEPS REGARDING POTENTIAL FURTHER DEVELOPMENT ARE ONGOING.  Full Article

Nanobiotix Q3 Revenue Down At 21,816 Euros
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - NANOBIOTIX SA ::Q3 REVENUES EUR 21,816 VERSUS EUR 33,018 YEAR AGO.  Full Article

Nanobiotix FY Net Loss Widens to ‍​26.1 Million Euros
Friday, 30 Mar 2018 

March 30 (Reuters) - NANOBIOTIX SA ::TOTAL REVENUE IN 2017 AMOUNTS TO EUR 3.7M VERSUS. EUR 5.4M IN 2016.CASH AVAILABLE AT DECEMBER 31, 2017 AMOUNTS TO EUR 47.2M..FY NET LOSS EUR ‍​26.1 MILLION VERSUS LOSS OF EUR 21.9 MILLION YEAR AGO.2018 SHOULD BE ANOTHER YEAR OF GROWTH.FY CORE OPERATING LOSS EUR 24.9 MILLION VERSUS LOSS OF EUR 21.9 MILLION YEAR AGO.EXPECTS TO PRESENT RESULTS OF ITS PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA IN Q2 2018..  Full Article

Nanobiotix FY Revenue Down At ‍​0.3 Million Euros
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - NANOBIOTIX SA ::FY REVENUE EUR ‍​0.3 MILLION VERSUS EUR 1.6 MILLION YEAR AGO.TO PRESENT RESULTS OF SOFT TISSUE SARCOMA PHASE II/III TRIAL WITH NBTXR3 IN Q2 2018‍​.TO START IN Q2 2018 PHASE I/II CLINICAL TRIAL OF NBTXR3 ACTIVATED BY RADIOTHERAPY WITH ANTI-PD1 ANTIBODY IN CANCER PATIENTS‍​.  Full Article

Nanobiotix Partners With The Providence Cancer Institute To Run Immunotherapeutic Preclinical Research In Pancreatic Cancers
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS.COLLABORATION WILL TAKE PLACE OVER COURSE OF ONE YEAR.WILL LAUNCH ITS FIRST CLINICAL TRIAL COMBINING NBTXR3 WITH IMMUNE CHECKPOINT INHIBITORS IN U.S..HAS RECEIVED APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND.  Full Article

Nanobiotix Q3 revenue down at 33.0‍​ million euros
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - NANOBIOTIX SA ::Q3 REVENUE EUR 33.0‍​ MILLION VERSUS EUR 58.6 MILLION YEAR AGO.  Full Article